297 related articles for article (PubMed ID: 25691036)
41. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
Aubart M; Ou P; Elie C; Canniffe C; Kutty S; Delos V; Graffigne C; de Montalembert M; Brousse V
J Pediatr Hematol Oncol; 2016 Oct; 38(7):497-502. PubMed ID: 27548334
[TBL] [Abstract][Full Text] [Related]
42. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
43. Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.
Vitrano A; Calvaruso G; Tesé L; Gioia F; Cassarà F; Campisi S; Butera F; Commendatore V; Rizzo M; Santoro V; Cigna V; Quota A; Bagnato S; Argento C; Fidone C; Schembari D; Gerardi C; Barbiera F; Bellisssima G; Giugno G; Polizzi G; Rosso R; Abbate G; Caruso V; Chiodi E; Gamberini MR; Giorgi B; Putti MC; Filosa A; De Ritis MR; Oliva E; Arcadi N; Fustaneo M; Mistretta L; Di Maggio R; Sacco M; Veronica DS; Giangreco A; Maggio A
Eur J Haematol; 2016 Oct; 97(4):361-70. PubMed ID: 26818147
[TBL] [Abstract][Full Text] [Related]
44. Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation.
Barcellini W; Zaninoni A; Gregorini AI; Soverini G; Duca L; Fattizzo B; Giannotta JA; Pedrotti P; Vercellati C; Marcello AP; Fermo E; Bianchi P; Cappellini MD
Br J Haematol; 2019 May; 185(3):523-531. PubMed ID: 30828802
[TBL] [Abstract][Full Text] [Related]
45. Transitioning Patients With Iron Overload From Exjade to Jadenu.
Tinsley SM; Hoehner-Cooper CM
J Infus Nurs; 2018; 41(3):171-175. PubMed ID: 29659464
[TBL] [Abstract][Full Text] [Related]
46. Iron Overload in Patients With Heavily Transfused Sickle Cell Disease-Correlation of Serum Ferritin With Cardiac T2
Alkindi S; Panjwani V; Al-Rahbi S; Al-Saidi K; Pathare AV
Front Med (Lausanne); 2021; 8():731102. PubMed ID: 34760898
[TBL] [Abstract][Full Text] [Related]
47. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
[TBL] [Abstract][Full Text] [Related]
48. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Chen CH; Shu KH; Yang Y
Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
[TBL] [Abstract][Full Text] [Related]
49. Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.
Stanley HM; Friedman DF; Webb J; Kwiatkowski JL
Pediatr Blood Cancer; 2016 Aug; 63(8):1414-8. PubMed ID: 27100139
[TBL] [Abstract][Full Text] [Related]
50. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation.
Jarisch A; Salzmann-Manrique E; Cario H; Grosse R; Soerensen J; Fischer R; Schulz A; Hammerstingl R; Wunderlich A; Bader P
Eur J Haematol; 2018 Dec; 101(6):791-797. PubMed ID: 30187571
[TBL] [Abstract][Full Text] [Related]
51. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
[TBL] [Abstract][Full Text] [Related]
52. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.
de Montalembert M; Ribeil JA; Brousse V; Guerci-Bresler A; Stamatoullas A; Vannier JP; Dumesnil C; Lahary A; Touati M; Bouabdallah K; Cavazzana M; Chauzit E; Baptiste A; Lefebvre T; Puy H; Elie C; Karim Z; Ernst O; Rose C
PLoS One; 2017; 12(3):e0172147. PubMed ID: 28257476
[TBL] [Abstract][Full Text] [Related]
53. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of deferasirox in myelodysplastic syndromes.
Breccia M; Alimena G
Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
[TBL] [Abstract][Full Text] [Related]
55. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
Remacha ÁF; Arrizabalaga B; Villegas A; Durán MS; Hermosín L; de Paz R; Garcia M; Diez Campelo M; Sanz G;
Ann Hematol; 2015 May; 94(5):779-87. PubMed ID: 25516455
[TBL] [Abstract][Full Text] [Related]
56. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
[TBL] [Abstract][Full Text] [Related]
57. Labile plasma iron, more practical and more sensitive to iron overload in myelodysplastic syndromes.
Gu S; Xv Y; Fei C; Xiao C; Guo J; Zhao Y; Xv F; Li X; Chang C
Hematology; 2017 Jan; 22(1):9-15. PubMed ID: 27684730
[TBL] [Abstract][Full Text] [Related]
58. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
Arandi N; Haghpanah S; Safaei S; Zahedi Z; Ashrafi A; Eatemadfar P; Zarei T; Radwan AH; Taher AT; Karimi M
Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
[TBL] [Abstract][Full Text] [Related]
59. Nontransferrin-bound iron in transfused patients with sickle cell disease.
Inati A; Musallam KM; Cappellini MD; Duca L; Taher AT
Int J Lab Hematol; 2011 Apr; 33(2):133-7. PubMed ID: 21382180
[TBL] [Abstract][Full Text] [Related]
60. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.
Majhail NS; Lazarus HM; Burns LJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):832-7. PubMed ID: 20079863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
